Evidence map›Paper›PMID 27768108›Full record

ArticleNature chemistry2016

Identification of (S)-selective transaminases for the asymmetric synthesis of bulky chiral amines.

Ioannis V Pavlidis, Martin S Weiß, Maika Genz, Paul Spurr, Steven P Hanlon, Beat Wirz, Hans Iding, Uwe T Bornscheuer

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Droplet Microfluidics and Directed Evolution of Enzymes: An Intertwined Journey.Angewandte Chemie (International ed. in English) · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biocatalytic access to betazole using a one-pot multienzymatic system in continuous flow.Green chemistry : an international journal and green chemistry resource : GC · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ioannis V PavlidisDepartment of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.ORCID 0000-0001-5811-368X
Martin S WeißDepartment of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.
Maika GenzDepartment of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.
Paul SpurrProcess Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland.
Steven P HanlonProcess Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland.
Beat WirzProcess Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland.
Hans IdingProcess Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland.
Uwe T BornscheuerDepartment of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.ORCID 0000-0003-0685-2696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of transaminases to access pharmaceutically relevant chiral amines is an attractive alternative to transition-metal-catalysed asymmetric chemical synthesis. However, one major challenge is their limited substrate scope. Here we report the creation of highly active and stereoselective transaminases starting from fold class I. The transaminases were developed by extensive protein engineering followed by optimization of the identified motif. The resulting enzymes exhibited up to 8,900-fold higher activity than the starting scaffold and are highly stereoselective (up to >99.9% enantiomeric excess) in the asymmetric synthesis of a set of chiral amines bearing bulky substituents. These enzymes should therefore be suitable for use in the synthesis of a wide array of potential intermediates for pharmaceuticals. We also show that the motif can be engineered into other protein scaffolds with sequence identities as low as 70%, and as such should have a broad impact in the field of biocatalytic synthesis and enzyme engineering.

Indexed as

AminesBinding SitesBiocatalysisCatalytic DomainKineticsMutagenesis, Site-DirectedProtein EngineeringQuinonesStereoisomerismSubstrate SpecificityTransaminasesAminesQuinonesTransaminases

Identifiers

PMID27768108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.